| LARYNX | | | | | | | | | | | |
|------------------|------------|---|--|--|--|--|--|--|--|--|--|
| | H | ospital Name/Address | Patient Name/Information | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| Type of St | naciman | | Histopathologic Type | | | | | | | | |
| Type of Specimen | | | Histopathologic Type Laterality: | | | | | | | | |
| Tumor Siz | ze | | Laterality: \square Bilateral \square Left \square Right | | | | | | | | |
| | | DEFINITIONS | | | | | | | | | |
| Clinical | Pathologic | Primary Tumor (T) | | | | | | | | | |
| | | TX Primary tumor canno | | | | | | | | | |
| | | TO No evidence of prima | y tumor | | | | | | | | |
| | | _ Tis | | | | | | | | | |
| | | | subsite of supraglottis with normal vocal cord mobility | | | | | | | | |
| | | T2 Tumor invades mucos | a of more than one adjacent subsite of supraglottis or glottis or region outside | | | | | | | | |
| | | the supraglottis (e.g., | nucosa of base of tongue, vallecula, medial wall of pyriform sinus) without | | | | | | | | |
| | | fixation of the larynx T3 Tumor limited to laryn | ay with vecal cord fivation and/or invades any of the following poetericaid area | | | | | | | | |
| | | | ex with vocal cord fixation and/or invades any of the following: postcricoid area, paraglottic space, and/or minor thyroid cartilage erosion (e.g., inner cortex) | | | | | | | | |
| | | | n the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft | | | | | | | | |
| | | tissues of neck including | ng deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus) | | | | | | | | |
| | | _ T4b Tumor invades prever <i>Glottis</i> | ebral space, encases carotid artery, or invades mediastinal structures | | | | | | | | |
| | | | ocal cord(s)(may involve anterior or posterior commissure) with normal mobility | | | | | | | | |
| | | | Tumor limited to one vocal cord | | | | | | | | |
| | | | Tumor involves both vocal cords | | | | | | | | |
| | | T2 Tumor extends to sup | aglottis and/or subglottis, or with impaired vocal cord mobility | | | | | | | | |
| | | | arynx with vocal cord fixation, and/or invades paraglottic space, and/or minor | | | | | | | | |
| | | thyroid cartilage erosion (e.g., inner cortex). _ T4a Tumor invades through the thyroid cartilage and/or invades tissues beyond the larynx (or invades tissues beyond the larynx). | | | | | | | | | |
| | | soft tissues of neck incl | soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus) | | | | | | | | |
| | | T4b Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures | | | | | | | | | |
| П | | Subglottis T1 Tumor limited to the | ubolottis | | | | | | | | |
| | | | al cord(s) with normal or impaired mobility | | | | | | | | |
| | | _ T3 Tumor limited to lary | Tumor limited to larynx with vocal cord fixation | | | | | | | | |
| | | T4a Tumor invades cricoid | Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus) | | | | | | | | |
| | | T4b Tumor invades prever | rebral space, encases carotid artery, or invades mediastinal structures | | | | | | | | |
| | | Regional Lymph Nodes (N) | 1 | | | | | | | | |
| | | NX Regional lymph nodes | cannot be assessed | | | | | | | | |
| | | No regional lymph no | | | | | | | | | |
| | | N1 Metastasis in a single i | osilateral lymph node, 3 cm or less in greatest dimension | | | | | | | | |
| | | N2 Metastasis in a single i | psilateral lymph node, more than 3 cm but not more limension, or in multiple ipsilateral lymph nodes, none | | | | | | | | |
| | | | atest dimension, or in bilateral or contralateral lymph | | | | | | | | |
| _ | | nodes, none more tha | n 6 cm in greatest dimension | | | | | | | | |
| | | | psilateral lymph node, more than 3 cm but not more | | | | | | | | |
| П | | than 6 cm in greatest of N2b Metastasis in multiple | imension ipsilateral lymph nodes, none more than 6 cm in | | | | | | | | |
| | | greatest dimension | ipshaterar tymph hodes, hohe more than o chi m | | | | | | | | |
| | | N2c Metastasis in bilateral | or contralateral lymph nodes, none more than 6 cm in | | | | | | | | |
| | | greatest dimension | node more than 6 cm in greatest dimension | | | | | | | | |
| | | • - | node, more than 6 cm in greatest dimension | | | | | | | | |
| | | Distant Metastasis (M) MY Distant metastasis can | not be assessed | | | | | | | | |
| | | MX Distant metastasis can M0 No distant metastasis | HOT DE ASSESSEU | | | | | | | | |
| | | M1 Distant metastasis | | | | | | | | | |
| | | Biopsy of metastatic s | te performed□Y□N | | | | | | | | |
| | | Source of pathologic r | netastatic specimen (continued on reverse side) | | | | | | | | |

LARYNX (continued)

| | | | | | | ··· | (commea) | | | | | | | | |
|--|---|---------------|-----------------------------|--------------|----------|-----|--------------------------------------|--|--|--|----------------|--|--|--|---|
| Clinical | Pathologic | Stage | Grouping | | | | _Notes | | | | | | | | |
| | | orage 0 | Tis | N0 | M0 | | Additional Descriptors | | | | | | | | |
| | | - I | T1 | N0 | M0 | | Lymphatic Vessel Invasion (L) | | | | | | | | |
| | | - II | T2 | N0 | M0 | | LX Lymphatic vessel invasion | | | | | | | | |
| | | - III | T3 | N0 | M0 | | cannot be assessed | | | | | | | | |
| | | - | T1 | N1 | M0 | | L0 No lymphatic vessel inva- sion | | | | | | | | |
| | | | T2 | N1 | M0 | | L1 Lymphatic vessel invasion | | | | | | | | |
| | | | T3 | N1 | M0 | | Venous Invasion (V) | | | | | | | | |
| | | _ IVA | T4a | N0 | M0 | | VX Venous invasion cannot be | | | | | | | | |
| | | | T4a | N1 | M0 | | assessed V0 No venous invasion | | | | | | | | |
| | | | T1 | N2 | M0 | | V1 Microscopic venous inva- | | | | | | | | |
| | | | T2 | N2 | M0 | | sion | | | | | | | | |
| | | | T3 | N2 | M0 | | V2 Macroscopic venous inva- sion | | | | | | | | |
| | | IVB | T4a T4b | N2 | M0 M0 | | Sion | | | | | | | | |
| | | _ 1 V D | Any T | Any N N3 | M0 | | | | | | | | | | |
| | | IVC | Any T | Any N | M1 | | | | | | | | | | |
| | - | _ | · | • | | | | | | | | | | | |
| | Г | Histo] GX | logic Grade (Grade cant | | | | | | | | | | | | |
| | | GA GI | Well differe | | eu | | | | | | | | | | |
| | | G2 | | differentiat | ed | | | | | | | | | | |
| | | G3 | Poorly diffe | | ·cu | | | | | | | | | | |
| Residual Tumor (R) RX Presence of residual tumor cannot be assessed R0 No residual tumor R1 Microscopic residual tumor R2 Macroscopic residual tumor | | | | | | | | | | | | | | | |
| | | | | | | | | | | | tional Descrip | | | | |
| | | | | | | | | | | | | | | I or pTNM classifications, the "m" suffi | X |
| | | | | | | | | and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. ☐ m suffix indicates the presence of multiple primary tumors in a single site and is | | | | | | | |
| | | | | | | | | | | | | | | | |
| recorded in parentheses: $pT(m)NM$. \Box y prefix indicates those cases in which classification is performed during or | | | | | | | | | | | | | | | |
| following initial multimodality therapy. The cTNM or pTNM category is identified | | | | | | | | | | | | | | | |
| | by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually | | | | | | | | | | | | | | |
| present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy. | | | | | | | | | | | | | | | |
| | | | | | | | | | r prefx indicates a recurrent tumor when staged after a disease-free interval, and | | | | | | |
| is identified by the "r" prefix: rTNM. | | | | | | | | | | | | | | | |
| | ☐ a prefix designates the stage determined at autopsy: aTNM. Prognostic Indicators (if applicable) | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

(continued)


ILLUSTRATION

Indicate on diagram primary tumor and regional nodes involved.

1.



2.




3.






5.



6.



Physician's Signature

Date_